ATYR aTyr: Earnings per share for the last twelve months

High R&D expenditures are temporarily limiting the profitability of aTyr Pharma, Inc. (ATYR), creating a plateau effect. Business revenues are based on the treatment of sarcoidosis via hospital networks and insurers. Earnings per share over the last four quarters demonstrate a trend where -21.65 serves as the target level. This chart confirms the expansion strategy of tRNA synthetase antibodies to capture a share of the immunopharmaceutical market.

A defensive portfolio is constructed using a strict filter of fundamental metrics to minimize capital risks. Net income per share (TTM) calculates the final annual financial result divided by the number of shares, isolating real returns from issuance noise. For aTyr Pharma, Inc. (ATYR), this indicator reflects the drug development stage and dependence on external investments. Negative values confirm the absence of current profits amid high clinical trial costs. By analyzing the rolling annual income per share, an investor assesses the capital burn rate.